Hemanext Inc. announced on September 7, 2022, that it has initiated the rollout of its Hemanext ONE®RBC (Red Blood Cell) Processing and Storage System in Europe.
Doctors have begun transfusing patients suffering from hematological malignancies using RBCs processed and stored with the Hemanext ONE® system, as part of a post-market clinical study in Bergen, Norway. This is a study designed to assess the initial safety effects of transfusing hypoxic RBCs in patients with acute burns and hematological malignancies, including MDS.
´´We believe the road to improved patient transfusions begins with storing RBCs under hypoxic conditions to limit oxidative damage and storage lesions. Our technology has the potential to facilitate efficient treatment of patients in need´´, stated Martin Cannon, Co-Founder and CEO of Hemanext.
Geir Hetland, MD, PhD, group leader, Department of Immunology and Transfusion Medicine, Oslo University Hospital, said: “It is thrilling to have a powerful new tool available that could improve transfusions. These real-world improvements in technology have the potential to transform blood and transfusion therapy.”
As societies around the world attempt to preserve and expand blood supplies, TIF, a strategic partner of Hemanext, is delighted to see the rollout of the Hemanext ONE® System and hopes that this innovative technology will soon be of benefit to thalassaemia and other patients that require chronic and high-volume transfusions, significantly improving their quality of life.